Sarepta Therapeutics (SRPT) — insider trading
Health Care · NASDAQ
Sarepta Therapeutics (SRPT) has 18 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 18 (latest 2026-09-04).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Wong Ryan Ho-Yan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 13,272 | $22.22 | $294.9K | Form 4 |
| 2026-09-04 | Rothfuss Cristin | Officer (EVP, General Counsel) | Shares withheld for taxes / exercise cost | 22,025 | $22.22 | $489.4K | Form 4 |
| 2026-09-04 | Rodino-Klapac Louise | Officer (President, R&D and Tech Ops) | Shares withheld for taxes / exercise cost | 21,423 | $22.22 | $476.0K | Form 4 |
| 2026-09-04 | Estepan Ian Michael | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 24,799 | $22.22 | $551.0K | Form 4 |
| 2026-07-28 | SEVERINO MICHAEL | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 2,224,342 | — | $0 | Form 4 |
| 2026-07-28 | SEVERINO MICHAEL | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 756,104 | — | — | Form 4 |
| 2026-06-04 | Barry Richard | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Chambers Michael Andrew | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Nicaise Claude | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Connelly Deirdre P | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | BEHRENS M KATHLEEN | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Wigzell Hans Lennart Rudolf | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Mayo Stephen | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-06-04 | Boor Kathryn Jean | Director | Grant / award / vesting | 16,875 | — | — | Form 4 |
| 2026-03-12 | Mayo Stephen | Director | Open-market sale | 7,239 | $17.02 | $123.2K | Form 4 |
| 2026-03-11 | Rodino-Klapac Louise | Officer (President, R&D and Tech Ops) | Shares withheld for taxes / exercise cost | 948 | $17.03 | $16.1K | Form 4 |
| 2026-03-11 | Wong Ryan Ho-Yan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 256 | $17.03 | $4.4K | Form 4 |
| 2026-03-11 | Estepan Ian Michael | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 1,097 | $17.03 | $18.7K | Form 4 |
Ask the chat about SRPT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Sarepta Therapeutics (SRPT).
Last updated 2026-09-04 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.